Božana Lončar-Brzak1, Marko Klobučar2, Irena Veliki-Dalić3, Ivan Sabol4, Sandra Kraljević Pavelić5, Božo Krušlin6, Marinka Mravak-Stipetić1. 1. School of Dental Medicine, Department of Oral Medicine, University of Zagreb, Zagreb, Croatia. 2. Department of Biotechnology and Centre for High-throughput technologies, University of Rijeka, Radmile Matejčić 2, 51000, Rijeka, Croatia. 3. Department of Pathology, Clinical Hospital for Tumours, Clinical Hospital Centre Sisters of Mercy, Zagreb, Croatia. 4. Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia. 5. Department of Biotechnology and Centre for High-throughput technologies, University of Rijeka, Radmile Matejčić 2, 51000, Rijeka, Croatia. sandrakp@biotech.uniri.hr. 6. School of Medicine, Department of Pathology, Clinical Hospital Centre Sisters of Mercy, University of Zagreb, Zagreb, Croatia.
Abstract
OBJECTIVES: The aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (OLP), oral squamous cell carcinoma (OSCC) and healthy mucosa. MATERIALS AND METHODS: Global protein profiling methods based on liquid chromatography coupled to mass spectrometry (LC-MS) were used, with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, as well as on analyses of IG2F and IGFR2 expression in healthy mucosa, OLP and OSCC tissues by comparative semi-quantitative immunohistochemistry. RESULTS: Mass spectrometry-based proteomics profiling of healthy mucosa, OLP and OSCC tissues (and accompanied histologically unaltered tissues, respectively) identified 55 extracellular matrix proteins. Twenty among identified proteins were common to all groups of samples. Expression of small leucine-rich extracellular matrix proteoglycans lumican and biglycan was found both in OSCC and OLP and they were validated by Western blot analysis as putative biomarkers. A significant increase (p < 0.05) of biglycan expression in OLP-AT group was determined in comparison with OLP-T group, while lumican showed significant up-regulation (p < 0.05) in OLP-T and OSCC-T groups vs. adjacent and control tissue groups. Biglycan expression was only determined in OSCC-AT group. Immunohistochemical analysis of IGF2 and IG2FR expression revealed no significant difference among groups of samples. CONCLUSION/CLINICAL RELEVANCE: Biglycan and lumican were identified as important pathogenesis biomarkers of OLP that point to its malignant potential.
OBJECTIVES: The aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (OLP), oral squamous cell carcinoma (OSCC) and healthy mucosa. MATERIALS AND METHODS: Global protein profiling methods based on liquid chromatography coupled to mass spectrometry (LC-MS) were used, with a special emphasis on evaluation of deregulated extracellular matrix molecules expression, as well as on analyses of IG2F and IGFR2 expression in healthy mucosa, OLP and OSCC tissues by comparative semi-quantitative immunohistochemistry. RESULTS: Mass spectrometry-based proteomics profiling of healthy mucosa, OLP and OSCC tissues (and accompanied histologically unaltered tissues, respectively) identified 55 extracellular matrix proteins. Twenty among identified proteins were common to all groups of samples. Expression of small leucine-rich extracellular matrix proteoglycans lumican and biglycan was found both in OSCC and OLP and they were validated by Western blot analysis as putative biomarkers. A significant increase (p < 0.05) of biglycan expression in OLP-AT group was determined in comparison with OLP-T group, while lumican showed significant up-regulation (p < 0.05) in OLP-T and OSCC-T groups vs. adjacent and control tissue groups. Biglycan expression was only determined in OSCC-AT group. Immunohistochemical analysis of IGF2 and IG2FR expression revealed no significant difference among groups of samples. CONCLUSION/CLINICAL RELEVANCE: Biglycan and lumican were identified as important pathogenesis biomarkers of OLP that point to its malignant potential.
Authors: Samantha L Eaton; Sarah L Roche; Maica Llavero Hurtado; Karla J Oldknow; Colin Farquharson; Thomas H Gillingwater; Thomas M Wishart Journal: PLoS One Date: 2013-08-30 Impact factor: 3.240
Authors: Gopal Iyer; James Price; Shay Bourgeois; Eric Armstrong; Shyhmin Huang; Paul M Harari Journal: BMC Cancer Date: 2016-10-06 Impact factor: 4.430
Authors: Pamela Maris; Arnaud Blomme; Ana Perez Palacios; Brunella Costanza; Akeila Bellahcène; Elettra Bianchi; Stephanie Gofflot; Pierre Drion; Giovanna Elvi Trombino; Emmanuel Di Valentin; Pino G Cusumano; Sylvie Maweja; Guy Jerusalem; Philippe Delvenne; Eric Lifrange; Vincent Castronovo; Andrei Turtoi Journal: PLoS Med Date: 2015-09-01 Impact factor: 11.069